Evidence map›Paper›PMID 32245264›Full record

ArticlePharmaceuticals (Basel, Switzerland)2020

Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses.

Martin D Bleasel, Gregory M Peterson

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05889793 (Emetine for Viral Outbreaks), which is not on this map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05889793 phase2 / phase3terminatednot on this mapstarted 2024, after this paper: background citation

Emetine for Viral Outbreaks: Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate Oral Emetine Against Covid-19 (EVOLVE)

TypeinterventionalSponsorJohns Hopkins UniversityRan2024 to 2025Enrolled4ConditionsCOVID-19ArmsEmetine Hydrochloride, Placebo
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 80 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
  13. Potential Antiviral Action of Alkaloids.Molecules (Basel, Switzerland) · 2022
    Review
  14. Drugs to limit Zika virus infection and implication for maternal-fetal health.Frontiers in virology (Lausanne, Switzerland) · 2022
    Article
  15. SARS-CoV-2 Antiviral Therapy.Clinical microbiology reviews · 2021
    Review
  16. Article
  17. Review
  18. Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2021
    Review
  19. Article
  20. Role of phytoconstituents in the management of COVID-19.Chemico-biological interactions · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Martin D BleaselSchool of Pharmacy and Pharmacology, University of Tasmania, Hobart Tasmania 7001, Australia.
Gregory M PetersonSchool of Pharmacy and Pharmacology, University of Tasmania, Hobart Tasmania 7001, Australia.ORCID 0000-0002-6764-3882
University of Tasmania · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 coronavirus is currently spreading around the globe with limited treatment options available. This article presents the rationale for potentially using old drugs (emetine, other ipecac alkaloids or analogues) that have been used to treat amoebiasis in the treatment of COVID-19. Emetine had amongst the lowest reported half-maximal effective concentration (EC

Indexed as

coronavirusCOVID-19dehydroemetineemetineipecacMERSrepurposing: antiviralSARStreatment

Identifiers

PMID32245264
PMCPMC7151655
OpenAlexW3010796628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.